[go: up one dir, main page]

BR112012028893A2 - composições imunoestimuladoras e de vacina - Google Patents

composições imunoestimuladoras e de vacina

Info

Publication number
BR112012028893A2
BR112012028893A2 BR112012028893A BR112012028893A BR112012028893A2 BR 112012028893 A2 BR112012028893 A2 BR 112012028893A2 BR 112012028893 A BR112012028893 A BR 112012028893A BR 112012028893 A BR112012028893 A BR 112012028893A BR 112012028893 A2 BR112012028893 A2 BR 112012028893A2
Authority
BR
Brazil
Prior art keywords
immunostimulatory
vaccine compositions
mananas
provides
present
Prior art date
Application number
BR112012028893A
Other languages
English (en)
Inventor
Alan Pietersz Geoffrey
Original Assignee
Ascend Biopharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010901997A external-priority patent/AU2010901997A0/en
Application filed by Ascend Biopharmaceuticals Pty Ltd filed Critical Ascend Biopharmaceuticals Pty Ltd
Publication of BR112012028893A2 publication Critical patent/BR112012028893A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

composições imunoestimuladoras e de vacina. a presente invenção fornece uma composição imunoestimuladora compreendendo mananas ,em que pelo menos 75% das mananas são maiores do que cerca de 1000 kda e/ou têm pelo menos 150 grupos aldeído .a presente invenção. a presente invenção também fornece a utilização desta composição em métodos de terapia de vacinação e de gene, juntamente com processos para sua preparação.
BR112012028893A 2010-05-10 2011-05-10 composições imunoestimuladoras e de vacina BR112012028893A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33308610P 2010-05-10 2010-05-10
AU2010901997A AU2010901997A0 (en) 2010-05-10 Immunostimulatory and vaccine compositions
AU2010904060A AU2010904060A0 (en) 2010-09-09 Immunostimulatory and vaccine compositions
PCT/AU2011/000542 WO2011140595A2 (en) 2010-05-10 2011-05-10 Immunostimulatory and vaccine compositions

Publications (1)

Publication Number Publication Date
BR112012028893A2 true BR112012028893A2 (pt) 2017-12-12

Family

ID=44914748

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012028893A BR112012028893A2 (pt) 2010-05-10 2011-05-10 composições imunoestimuladoras e de vacina

Country Status (9)

Country Link
US (1) US9597392B2 (pt)
EP (1) EP2574170A4 (pt)
JP (1) JP6096111B2 (pt)
CN (1) CN102985095B (pt)
AU (1) AU2011226992B2 (pt)
BR (1) BR112012028893A2 (pt)
CA (1) CA2798856C (pt)
RU (1) RU2578420C2 (pt)
WO (1) WO2011140595A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3061462B1 (en) 2007-07-02 2019-02-27 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
JP2014532799A (ja) * 2011-11-09 2014-12-08 アセンド・バイオファーマシューティカルズ・リミテッド 免疫調節結合体
WO2014031178A1 (en) 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
ES2503516B1 (es) 2013-04-03 2015-09-09 Inmunotek, S.L. Complejo inmunogénico para vacunación y método de obtención
AU2016205215B2 (en) 2015-01-09 2021-03-11 Etubics Corporation Methods and compositions for combination immunotherapy
EP3256140B1 (en) 2015-01-09 2020-04-01 Etubics Corporation Compositions for ebola virus vaccination
WO2016172249A1 (en) * 2015-04-20 2016-10-27 Etubics Corporation Methods and compositions for combination immunotherapy
AU2017291321B2 (en) 2016-06-22 2020-06-18 Alkermes, Inc. Compositions and methods for modulating IL-10 immunostimulatory and anti-inflammatory properties
KR20210044805A (ko) * 2018-08-06 2021-04-23 닐슨 바이오사이언스, 아이엔씨. 사마귀의 치료
US11197910B1 (en) * 2020-08-19 2021-12-14 Vitruviae LLC Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases
AU2022234358A1 (en) * 2021-03-12 2023-10-19 Children's Medical Center Corporation Polysaccharide adjuvants for virus vaccines
CN113616799B (zh) * 2021-07-13 2023-08-29 中国科学院长春应用化学研究所 一种疫苗载体、其制备方法及应用
WO2024117232A1 (ja) * 2022-11-30 2024-06-06 国立大学法人九州大学 免疫原性複合体及び医薬組成物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3362951A (en) 1965-12-21 1968-01-09 Farkas Alexander Polysaccharide product derived from the juice of the aloe plant and methods for preparing same
US5308838A (en) 1982-05-07 1994-05-03 Carrington Laboratories, Inc. Uses of aloe products
US4735935A (en) 1985-12-17 1988-04-05 Carrington Laboratories, Inc. Process for preparation of aloe products products, produced thereby and compositions thereof
US4861761A (en) 1984-06-28 1989-08-29 Dr. Madis Laboratories, Inc. Aloeferon isolation, manufacturing and its applications
FR2573656B1 (fr) 1984-11-29 1987-02-27 Sanofi Sa Medicament comportant en tant qu'association au moins une immunotoxine et au moins un polymere contenant du mannose
CA1339204C (en) 1987-01-07 1997-08-05 Joyce Taylor-Papadimitriou Mucin core polypeptide, antibodies and probes
US6054438A (en) 1987-01-07 2000-04-25 Imperial Cancer Research Technology Limited Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
EP0740704A1 (en) 1994-01-27 1996-11-06 University Of Massachusetts Medical Center Immunization by inoculation of dna transcription unit
US5939400A (en) 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
WO1997044446A1 (en) 1996-05-24 1997-11-27 University Of Maryland At Baltimore Dna vaccines for eliciting a mucosal immune response
US5824659A (en) 1996-09-04 1998-10-20 Board Of Regents, The University Of Texas System Cytoprotective oligosaccharide from Aloe preventing damage to the skin immune system by UV radiation
CA2275259C (en) 1996-12-20 2008-02-12 Merck & Co., Inc. Formulations of recombinant papillomavirus vaccines
ES2357960T3 (es) 1997-05-08 2011-05-04 Oncothyreon Inc. Procedimiento para generar células t activadas y células presentadoras de antígenos pulsadas con antígenos.
US6573245B1 (en) 1998-04-28 2003-06-03 Galenica Pharmaceuticals, Inc. Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
DE19917195B4 (de) 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
EP1210430B1 (en) 1999-09-08 2006-08-30 Transgene S.A. Muc-1 derived peptides
CA2399026A1 (en) 2000-02-01 2001-08-09 The Austin Research Institute Mucin-1 derived antigens and their use in immunotherapy
WO2008037033A1 (en) 2006-09-29 2008-04-03 The Macfarlane Burnet Institute For Medical Research And Public Health Limited Flu vaccine admixture of mannan and flu antigen
AUPQ797700A0 (en) 2000-06-06 2000-06-29 Austin Research Institute, The Vaccine
AU2002218748A1 (en) 2000-07-10 2002-01-21 The University Of Mississippi High molecular weight polysaccharide fraction from aloe vera with immunostimulatory activity
ES2220800T3 (es) * 2000-08-10 2004-12-16 Ocean Nutrition Canada Ltd. Preparaciones de chlorella que muestran propiedades inmunomoduladoras.
ES2355819T3 (es) 2002-08-15 2011-03-31 3M Innovative Properties Company Composiciones inmunoestimuladoras y métodos para estimular una respuesta inmune.
EP2181595A1 (en) 2002-08-16 2010-05-05 Yeda Research And Development Company Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
WO2005044861A1 (en) * 2003-10-31 2005-05-19 Wyeth Holdings Corporation Polysaccharides of helicobacter pylori
EP1697515A4 (en) 2003-11-12 2008-02-06 Austin Research Inst CONJUGATE DNA-EXCIPIENT
US20060084629A1 (en) 2004-10-15 2006-04-20 Alvin Needleman Immune system activating formula composed of selected long chain polysaccharides from natural sources
JP2006241023A (ja) * 2005-03-01 2006-09-14 Asahi Breweries Ltd 消化管組織における抗菌ペプチドの発現誘導または産生促進剤
JP2006241020A (ja) * 2005-03-01 2006-09-14 Asahi Breweries Ltd 免疫系賦活剤
EP3085373A1 (en) 2006-02-22 2016-10-26 3M Innovative Properties Company Immune response modifier conjugates
CA2648099C (en) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
EP2046812A4 (en) 2006-07-25 2010-04-14 4G Vaccines Pty Ltd A CANCER VACCINE CONTAINING PEPTIDE DERIVED FROM MUCIN-1 (MUC1) T-CELL EPITOP
US20080152648A1 (en) 2006-09-26 2008-06-26 Alexion Pharmaceuticals, Inc. Compositions and methods for enhancing an adjuvant
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles

Also Published As

Publication number Publication date
AU2011226992A1 (en) 2011-11-24
CN102985095B (zh) 2016-05-18
WO2011140595A3 (en) 2012-01-05
RU2578420C2 (ru) 2016-03-27
CA2798856C (en) 2019-04-23
US20130251741A1 (en) 2013-09-26
CA2798856A1 (en) 2011-11-17
EP2574170A4 (en) 2013-11-20
EP2574170A2 (en) 2013-04-03
CN102985095A (zh) 2013-03-20
US9597392B2 (en) 2017-03-21
RU2012152952A (ru) 2014-06-20
AU2011226992B2 (en) 2012-03-22
WO2011140595A2 (en) 2011-11-17
JP2013527854A (ja) 2013-07-04
JP6096111B2 (ja) 2017-03-15

Similar Documents

Publication Publication Date Title
BR112012028893A2 (pt) composições imunoestimuladoras e de vacina
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
WO2017191274A3 (en) Rna encoding a therapeutic protein
MX2022005291A (es) Vacunas para el tratamiento y prevencion del cancer.
EP4241784A3 (en) Artificial nucleic acid molecules for improved protein expression
EA201890355A1 (ru) Новые способы индукции иммунного ответа
BR112022004047A2 (pt) Proteínas de ligação multiespecíficas para o tratamento de câncer
BR112018006006A2 (pt) receptores de antígeno, cadeias peptídicas, células recombinantes, métodos para produzir uma célula que expressa um receptor de antígeno e para o tratamento de uma doença, ácidos nucleicos e composição farmacêutica
BR112014011896A2 (pt) agentes de rnai, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr)
EA201171220A1 (ru) Мутанты fgf21 и их применение
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
BR112019024747A2 (pt) formulações de dose fixa
BR112012018951C8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
BR112017012482A2 (pt) copolímero estático, composição, uso de um copolímero, e, métodos para liberar um ácido nucleico a uma célula ou tecido alvo e para a produção do copolímero.
BR112014032636A2 (pt) Vacinas atenuadas de streptococcus suis e métodos de produção e usos das mesmas
BR112018000632A2 (pt) moléculas de anticorpo que ligam a cd79
MX2017014730A (es) Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3).
MX2009004243A (es) Nuevas proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal.
BR112012013329A2 (pt) composição oral e método para o tratamento de uma doença ou condição do tecido mole da cavidade oral
MX360085B (es) Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso.
BR112015000585A8 (pt) método para preparar uma cepa mutante de mycoplasma hyopneumoniae, vetores, cepa mutante, vacina, kit de vacinação e usos do vetor e da cepa mutante
BR112012022337A2 (pt) composição e respectivos método de preparação e uso de quantidade eficaz
BR112017001417A2 (pt) variantes de proteína de ligação ao fator h e métodos para uso das mesmas
BR112018008840A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
PH12017501100B1 (en) Recombinant swinepox virus and vaccines

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]